Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, United States; Tufts University Medical Center, United States.
Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, United States; L.V. Prasad Eye Institute, Hyderabad, India.
Ocul Surf. 2021 Jul;21:16-18. doi: 10.1016/j.jtos.2021.04.009. Epub 2021 Apr 28.
The purpose of this study is to compare the severity of chronic ocular complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) induced by lamotrigine (LT) vs. trimethoprim-sulfamethoxazole (TS).
This retrospective cross-sectional study evaluated all SJS/TEN patients treated within our hospital network from 2008 to 2018. Inclusion criteria included patients with reactions identified as caused by either LT or TS, and patients with at least one ophthalmology follow up in the chronic phase (≥3 months from disease onset). Primary outcome measures included LogMAR best-corrected VA at most recent visit and the presence or absence of severe ocular complications (SOC). Secondary outcome measures included chronic ocular complication severity scores using a modified Sotozono scoring system.
Forty-eight eyes of 24 patients were included in the study. The mean duration of follow-up was 39.50 ± 35.62 vs. 48.17 ± 33.09 months, respectively (p = 0.482). The LT group had worse average VA at the most recent visit (LogMAR VA; 0.508 vs. 0.041, p < 0.0001) and had a higher prevalence of SOCs (66.7% vs. 8.3%, p = 0.0038). The LT group scored worse on Sotozono chronic complications scores for the cornea (1.875 vs. 0.5, p = 0.0018), eyelid margin (5.583 vs.3.083, p = 0.0010), and overall condition (8.500 vs. 4.833, p = 0.0015). Sub-analyses showed that a moderate or severe acute ocular severity score was a significant predictor of chronic outcomes.
Compared to patients with TS-induced SJS/TEN, patients with LT-induced SJS/TEN developed worse chronic ocular complications on several parameters. Future prospective studies are warranted to provide additional insight into the drug type as a predictor of chronic ocular complications.
本研究旨在比较拉莫三嗪(LT)与甲氧苄啶-磺胺甲噁唑(TS)引起的史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症(SJS/TEN)的慢性眼部并发症的严重程度。
这项回顾性的横断面研究评估了 2008 年至 2018 年期间在我们医院网络内治疗的所有 SJS/TEN 患者。纳入标准包括反应由 LT 或 TS 引起的患者,以及在慢性期(疾病发作后至少 3 个月)至少有一次眼科随访的患者。主要结局指标包括最近一次就诊时的 LogMAR 最佳矫正视力(VA)和是否存在严重眼部并发症(SOC)。次要结局指标包括使用改良 Sotozono 评分系统评估慢性眼部并发症严重程度评分。
研究纳入了 24 例患者的 48 只眼。平均随访时间分别为 39.50±35.62 个月和 48.17±33.09 个月(p=0.482)。LT 组最近一次就诊时的平均 VA 更差(LogMAR VA:0.508 与 0.041,p<0.0001),SOC 发生率更高(66.7%与 8.3%,p=0.0038)。LT 组在角膜(1.875 与 0.5,p=0.0018)、睑缘(5.583 与 3.083,p=0.0010)和总体状况(8.500 与 4.833,p=0.0015)的 Sotozono 慢性并发症评分上得分更差。亚分析显示,中度或重度急性眼部严重程度评分是慢性结局的显著预测因素。
与 TS 引起的 SJS/TEN 患者相比,LT 引起的 SJS/TEN 患者在几个参数上发生了更严重的慢性眼部并发症。需要进一步进行前瞻性研究,以提供更多关于药物类型作为慢性眼部并发症预测因素的信息。